120 related articles for article (PubMed ID: 29508536)
1. Chronic myeloid leukemia, BCR-ABL1-positive with CALR and MPL mutations.
Klairmont MM; Cheng J; Schwartzberg L; Ho HH; Gradowski JF
Int J Lab Hematol; 2018 Jun; 40(3):e41-e42. PubMed ID: 29508536
[No Abstract] [Full Text] [Related]
2. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
3. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.
Diamond JM; de Almeida AM; Belo HJ; da Costa MP; Cabeçadas JM; Abecasis MM
Ann Hematol; 2016 Dec; 95(12):2101-2104. PubMed ID: 27699446
[No Abstract] [Full Text] [Related]
4. Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia.
da Costa VEF; de Oliveira RD; Traina F; Chahud F; Palma LC; de Figueiredo-Pontes LL
Br J Haematol; 2020 Feb; 188(3):e21-e23. PubMed ID: 31681999
[No Abstract] [Full Text] [Related]
5. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?
Gorbenko AS; Stolyar MA; Olkhovskiy IA; Vasiliev EV; Mikhalev MA
Clin Chem Lab Med; 2019 Mar; 57(4):e60-e62. PubMed ID: 30157024
[No Abstract] [Full Text] [Related]
6. Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation.
Xia D; Hsi ED; Dal Cin P; Hasserjian RP
Am J Hematol; 2019 Apr; 94(4):504-505. PubMed ID: 30105753
[No Abstract] [Full Text] [Related]
7. Peptide nucleic acid probe-based fluorescence melting curve analysis for rapid screening of common JAK2, MPL, and CALR mutations.
Park J; Song M; Jang W; Chae H; Lee GD; Kim K; Park H; Kim M; Kim Y
Clin Chim Acta; 2017 Feb; 465():82-90. PubMed ID: 27939919
[TBL] [Abstract][Full Text] [Related]
8. A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.
Cabagnols X; Cayuela JM; Vainchenker W
N Engl J Med; 2015 Feb; 372(7):688-90. PubMed ID: 25671272
[No Abstract] [Full Text] [Related]
9. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
Dong L; Shen XL; Wei W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
[TBL] [Abstract][Full Text] [Related]
11. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
[TBL] [Abstract][Full Text] [Related]
12. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
14. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
15. [A case of chronic myeloid leukemia with positive CALR gene].
Han Y; Song Y; Wang Y; Chai Y; Zeng PY; Yue LL; Wu CY
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):872. PubMed ID: 33190451
[No Abstract] [Full Text] [Related]
16. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm.
Chen Z; Wang W; Verstovsek S; Cortes JE; Medeiros LJ; Hu S
Int J Lab Hematol; 2015 Dec; 37(6):e150-2. PubMed ID: 26086872
[No Abstract] [Full Text] [Related]
19. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
Masubuchi N; Araki M; Yang Y; Hayashi E; Imai M; Edahiro Y; Hironaka Y; Mizukami Y; Kihara Y; Takei H; Nudejima M; Koike M; Ohsaka A; Komatsu N
Leukemia; 2020 Feb; 34(2):499-509. PubMed ID: 31462733
[TBL] [Abstract][Full Text] [Related]
20. CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.
Bonzheim I; Mankel B; Klapthor P; Schmidt J; Hinrichsen T; Wachter O; Fend F; Quintanilla-Martinez L
Blood; 2015 Apr; 125(14):2309-11. PubMed ID: 25838280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
